<?xml version="1.0" encoding="utf-8"?> <feed xmlns:dc="http://dublincore.org/documents/dcmi-namespace/" xmlns:media="http://search.yahoo.com/mrss/" xmlns="http://www.w3.org/2005/Atom"> <title type="text">Acura Pharmaceuticals, Inc.</title> <subtitle type="text">Contains the last 20 releases</subtitle> <id>uuid:8410b6a6-31f7-408d-b195-77b74afce874;id=41763</id> <rights type="text">Copyright 2022, Acura Pharmaceuticals, Inc.</rights> <updated>2022-03-01T11:30:00Z</updated> <author> <name>newsdesk@globenewswire.com (NewsDesk)</name> <uri>http://www.globenewswire.com/LegacyRss?Length=4</uri> <email>newsdesk@globenewswire.com</email> </author> <link rel="alternate" href="https://www.globenewswire.com/atomfeed/organization/Lt2gWortPyToPJD2CNUXrA==" /> <link rel="self" href="https://www.globenewswire.com/atomfeed/organization/Lt2gWortPyToPJD2CNUXrA==" /> <entry> <id>https://www.globenewswire.com/news-release/2022/03/01/2394022/10047/en/Acura-Pharmaceuticals-and-AD-Pharma-Amend-License-to-LIMITx-LTX-03.html</id> <title type="text">Acura Pharmaceuticals and AD Pharma Amend License to LIMITx™ LTX-03</title> <published>2022-03-01T11:30:00Z</published> <updated>2024-12-15T00:21:40Z</updated> <link rel="alternate" href="https://www.globenewswire.com/news-release/2022/03/01/2394022/10047/en/Acura-Pharmaceuticals-and-AD-Pharma-Amend-License-to-LIMITx-LTX-03.html" /> <category term="Other OTC:ACUR" scheme="https://www.globenewswire.com/rss/stock" /> <category term="US00509L8028" scheme="https://www.globenewswire.com/rss/ISIN" /> <content type="html"><![CDATA[Amendment Extends NDA Acceptance Date <pre>Amendment Extends NDA Acceptance Date</pre>]]></content> <dc:identifier>2394022</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>Acura Pharmaceuticals, Inc.</dc:contributor> <dc:modified>Tue, 01 Mar 2022 11:30 GMT</dc:modified> <dc:subject>Health</dc:subject> </entry> <entry> <id>https://www.globenewswire.com/news-release/2022/02/14/2384235/10047/en/Acura-Pharmaceuticals-Provides-Development-Update-on-LTX-03.html</id> <title type="text">Acura Pharmaceuticals Provides Development Update on LTX-03</title> <published>2022-02-14T11:30:00Z</published> <updated>2024-12-15T00:21:40Z</updated> <link rel="alternate" href="https://www.globenewswire.com/news-release/2022/02/14/2384235/10047/en/Acura-Pharmaceuticals-Provides-Development-Update-on-LTX-03.html" /> <category term="Other OTC:ACUR" scheme="https://www.globenewswire.com/rss/stock" /> <category term="US00509L8028" scheme="https://www.globenewswire.com/rss/ISIN" /> <content type="html"><![CDATA[<p align="justify">PALATINE, Ill., Feb. 14, 2022 (GLOBE NEWSWIRE) -- Acura Pharmaceuticals, Inc. (OTCQB: ACUR) today announced that the LTX-03 (hydrocodone bitartrate and acetaminophen) tablets using Acura’s LIMITx technology manufactured in the three New Drug Application (“NDA”) required registration batches successfully passed testing at the six month time point in an ongoing shelf life study when stored at normal temperature and humidity conditions, also known as controlled room temperature (“CRT”). The patented LIMITx technology is a composition of inactive ingredients formulated in a manner that reduces the risks of drug overdose by reducing peak drug levels when inappropriate numbers of tablets are ingested.<br></p>]]></content> <dc:identifier>2384235</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>Acura Pharmaceuticals, Inc.</dc:contributor> <dc:modified>Mon, 14 Feb 2022 11:30 GMT</dc:modified> <dc:subject>Health</dc:subject> <dc:subject>Product / Services Announcement</dc:subject> </entry> <entry> <id>https://www.globenewswire.com/news-release/2021/11/15/2334763/10047/en/Acura-Pharmaceuticals-Announces-Third-Quarter-2021-Financial-Results.html</id> <title type="text">Acura Pharmaceuticals Announces Third Quarter 2021 Financial Results</title> <published>2021-11-15T21:15:00Z</published> <updated>2024-12-15T00:21:40Z</updated> <link rel="alternate" href="https://www.globenewswire.com/news-release/2021/11/15/2334763/10047/en/Acura-Pharmaceuticals-Announces-Third-Quarter-2021-Financial-Results.html" /> <category term="Other OTC:ACUR" scheme="https://www.globenewswire.com/rss/stock" /> <category term="US00509L8028" scheme="https://www.globenewswire.com/rss/ISIN" /> <content type="html"><![CDATA[<p align="left">PALATINE, Ill., Nov. 15, 2021 (GLOBE NEWSWIRE) -- Acura Pharmaceuticals, Inc. (OTCQB: ACUR), an innovative drug delivery company engaged in the research, development and commercialization of technologies and products intended to address safe use of medications, announced today financial results for the three and nine months ended September 30, 2021.</p>]]></content> <dc:identifier>2334763</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>Acura Pharmaceuticals, Inc.</dc:contributor> <dc:modified>Mon, 15 Nov 2021 21:15 GMT</dc:modified> <dc:subject>Earnings Releases and Operating Results</dc:subject> <dc:subject>Health</dc:subject> </entry> <entry> <id>https://www.globenewswire.com/news-release/2021/08/16/2281550/10047/en/Acura-Pharmaceuticals-Announces-Second-Quarter-2021-Financial-Results.html</id> <title type="text">Acura Pharmaceuticals Announces Second Quarter 2021 Financial Results</title> <published>2021-08-16T20:15:00Z</published> <updated>2024-12-15T00:21:40Z</updated> <link rel="alternate" href="https://www.globenewswire.com/news-release/2021/08/16/2281550/10047/en/Acura-Pharmaceuticals-Announces-Second-Quarter-2021-Financial-Results.html" /> <category term="Other OTC:ACUR" scheme="https://www.globenewswire.com/rss/stock" /> <category term="US00509L8028" scheme="https://www.globenewswire.com/rss/ISIN" /> <content type="html"><![CDATA[<p align="justify">PALATINE, Ill., Aug. 16, 2021 (GLOBE NEWSWIRE) -- Acura Pharmaceuticals, Inc. (OTCQB: ACUR), an innovative drug delivery company engaged in the research, development and commercialization of technologies and products intended to address safe use of medications, announced today financial results for the three and six months ended June 30, 2021.<br></p>]]></content> <dc:identifier>2281550</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>Acura Pharmaceuticals, Inc.</dc:contributor> <dc:modified>Mon, 16 Aug 2021 20:15 GMT</dc:modified> <dc:subject>Earnings Releases and Operating Results</dc:subject> </entry> <entry> <id>https://www.globenewswire.com/news-release/2021/07/26/2268955/10047/en/Acura-Pharmaceuticals-and-AD-Pharma-Amend-License-to-LIMITx-LTX-03.html</id> <title type="text">Acura Pharmaceuticals and AD Pharma Amend License to LIMITx™ LTX-03</title> <published>2021-07-26T20:15:00Z</published> <updated>2024-12-15T00:21:40Z</updated> <link rel="alternate" href="https://www.globenewswire.com/news-release/2021/07/26/2268955/10047/en/Acura-Pharmaceuticals-and-AD-Pharma-Amend-License-to-LIMITx-LTX-03.html" /> <category term="Other OTC:ACUR" scheme="https://www.globenewswire.com/rss/stock" /> <category term="US00509L8028" scheme="https://www.globenewswire.com/rss/ISIN" /> <content type="html"><![CDATA[Amendment Extends NDA Acceptance Date <pre>Amendment Extends NDA Acceptance Date</pre>]]></content> <dc:identifier>2268955</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>Acura Pharmaceuticals, Inc.</dc:contributor> <dc:modified>Mon, 26 Jul 2021 20:15 GMT</dc:modified> <dc:subject>Licensing Agreements</dc:subject> </entry> <entry> <id>https://www.globenewswire.com/news-release/2021/06/14/2246817/10047/en/Acura-Pharmaceuticals-Announces-Conversion-of-Debt.html</id> <title type="text">Acura Pharmaceuticals Announces Conversion of Debt</title> <published>2021-06-14T20:10:00Z</published> <updated>2024-12-15T00:21:40Z</updated> <link rel="alternate" href="https://www.globenewswire.com/news-release/2021/06/14/2246817/10047/en/Acura-Pharmaceuticals-Announces-Conversion-of-Debt.html" /> <category term="Other OTC:ACUR" scheme="https://www.globenewswire.com/rss/stock" /> <category term="US00509L8028" scheme="https://www.globenewswire.com/rss/ISIN" /> <content type="html"><![CDATA[<p align="justify">PALATINE, Ill., June 14, 2021 (GLOBE NEWSWIRE) -- Acura Pharmaceuticals, Inc. (OTCQB: ACUR) today announced that Abuse Deterrent Pharma, LLC (“AD Pharma”) has converted the entire principle and accrued interest of its Secured Promissory Note (the “Note”) with the Company into shares of the Company’s common stock. Effective with this conversion, the Note is retired and the Company is working with AD Pharma to release their security interest in all the Company’s assets. Under the terms of the Note, AD Pharma elected to convert the $6.9 million outstanding principal and accrued interest at $0.16 per share yielding 42,984,375 newly issued common shares. The Company’s total common shares outstanding is now 65,089,043.<br></p>]]></content> <dc:identifier>2246817</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>Acura Pharmaceuticals, Inc.</dc:contributor> <dc:modified>Mon, 14 Jun 2021 20:10 GMT</dc:modified> <dc:subject>Changes in company's own shares</dc:subject> </entry> <entry> <id>https://www.globenewswire.com/news-release/2021/06/07/2242538/10047/en/Acura-Pharmaceuticals-Provides-Development-Update-on-LTX-03.html</id> <title type="text">Acura Pharmaceuticals Provides Development Update on LTX-03</title> <published>2021-06-07T10:00:00Z</published> <updated>2024-12-15T00:21:40Z</updated> <link rel="alternate" href="https://www.globenewswire.com/news-release/2021/06/07/2242538/10047/en/Acura-Pharmaceuticals-Provides-Development-Update-on-LTX-03.html" /> <category term="Other OTC:ACUR" scheme="https://www.globenewswire.com/rss/stock" /> <category term="US00509L8028" scheme="https://www.globenewswire.com/rss/ISIN" /> <content type="html"><![CDATA[<p align="justify">PALATINE, Ill., June 07, 2021 (GLOBE NEWSWIRE) -- Acura Pharmaceuticals, Inc. (OTCQB: ACUR) today announced the successful completion of three NDA required registration batches of the to-be-marketed LTX-03 formulation. The LTX-03 tablets were manufactured on commercial scale equipment and passed all requisite quality assurance tests. The LTX-03 tablets from these batches will be used in a six month shelf life stability study, which will commence immediately, and in human clinical studies, which will commence after an update to the Investigation New Drug application on file with the Food and Drug Administration (FDA).<br></p>]]></content> <dc:identifier>2242538</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>Acura Pharmaceuticals, Inc.</dc:contributor> <dc:modified>Mon, 07 Jun 2021 10:00 GMT</dc:modified> <dc:subject>Health</dc:subject> <dc:subject>Product / Services Announcement</dc:subject> </entry> <entry> <id>https://www.globenewswire.com/news-release/2021/05/17/2231105/10047/en/Acura-Pharmaceuticals-Announces-First-Quarter-Ended-March-31-2021-Financial-Results.html</id> <title type="text">Acura Pharmaceuticals Announces First Quarter Ended March 31, 2021 Financial Results</title> <published>2021-05-17T20:15:00Z</published> <updated>2024-12-15T00:21:40Z</updated> <link rel="alternate" href="https://www.globenewswire.com/news-release/2021/05/17/2231105/10047/en/Acura-Pharmaceuticals-Announces-First-Quarter-Ended-March-31-2021-Financial-Results.html" /> <category term="Other OTC:ACUR" scheme="https://www.globenewswire.com/rss/stock" /> <category term="US00509L8028" scheme="https://www.globenewswire.com/rss/ISIN" /> <content type="html"><![CDATA[<p align="justify">PALATINE, Ill., May 17, 2021 (GLOBE NEWSWIRE) -- Acura Pharmaceuticals, Inc. (OTCQB: ACUR), an innovative drug delivery company engaged in the research, development and commercialization of technologies and products intended to address safe use of medications, announced today financial results for its first quarter ended March 31, 2021.<br></p>]]></content> <dc:identifier>2231105</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>Acura Pharmaceuticals, Inc.</dc:contributor> <dc:modified>Mon, 17 May 2021 20:15 GMT</dc:modified> <dc:subject>Company Announcement</dc:subject> </entry> <entry> <id>https://www.globenewswire.com/news-release/2021/03/31/2202869/10047/en/Acura-Pharmaceuticals-Announces-Fourth-Quarter-and-Full-Year-2020-Financial-Results.html</id> <title type="text">Acura Pharmaceuticals Announces Fourth Quarter and Full Year 2020 Financial Results</title> <published>2021-03-31T20:15:00Z</published> <updated>2024-12-15T00:21:40Z</updated> <link rel="alternate" href="https://www.globenewswire.com/news-release/2021/03/31/2202869/10047/en/Acura-Pharmaceuticals-Announces-Fourth-Quarter-and-Full-Year-2020-Financial-Results.html" /> <category term="Other OTC:ACUR" scheme="https://www.globenewswire.com/rss/stock" /> <category term="US00509L8028" scheme="https://www.globenewswire.com/rss/ISIN" /> <content type="html"><![CDATA[<p align="justify">PALATINE, Ill., March 31, 2021 (GLOBE NEWSWIRE) -- Acura Pharmaceuticals, Inc. (OTCQB: ACUR), an innovative drug delivery company engaged in the research, development and commercialization of technologies and products intended to address safe use of medications, announced today financial results for the three and twelve months ended December 31, 2020.<br></p>]]></content> <dc:identifier>2202869</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>Acura Pharmaceuticals, Inc.</dc:contributor> <dc:modified>Wed, 31 Mar 2021 20:15 GMT</dc:modified> <dc:subject>Earnings Releases and Operating Results</dc:subject> </entry> <entry> <id>https://www.globenewswire.com/news-release/2020/11/16/2127777/10047/en/Acura-Pharmaceuticals-Announces-Third-Quarter-2020-Financial-Results.html</id> <title type="text">Acura Pharmaceuticals Announces Third Quarter 2020 Financial Results</title> <published>2020-11-16T21:15:00Z</published> <updated>2024-12-15T00:21:40Z</updated> <link rel="alternate" href="https://www.globenewswire.com/news-release/2020/11/16/2127777/10047/en/Acura-Pharmaceuticals-Announces-Third-Quarter-2020-Financial-Results.html" /> <category term="Other OTC:ACUR" scheme="https://www.globenewswire.com/rss/stock" /> <category term="US00509L8028" scheme="https://www.globenewswire.com/rss/ISIN" /> <content type="html"><![CDATA[<p align="justify">PALATINE, Ill., Nov. 16, 2020 (GLOBE NEWSWIRE) -- Acura Pharmaceuticals, Inc. (OTCQB: ACUR), a specialty pharmaceutical company engaged in the research, development and commercialization of technologies and product candidates intended to mitigate the risk of outcomes associated with product misuse, announced today financial results for the three and nine months ended September 30, 2020.<br></p>]]></content> <dc:identifier>2127777</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>Acura Pharmaceuticals, Inc.</dc:contributor> <dc:modified>Mon, 16 Nov 2020 21:15 GMT</dc:modified> <dc:subject>Earnings Releases and Operating Results</dc:subject> </entry> <entry> <id>https://www.globenewswire.com/news-release/2020/10/28/2116311/10047/en/Acura-Pharmaceuticals-and-AD-Pharma-Amend-License-to-LIMITx-LTX-03.html</id> <title type="text">Acura Pharmaceuticals and AD Pharma Amend License to LIMITx™ LTX-03 </title> <published>2020-10-28T20:15:00Z</published> <updated>2024-12-15T00:21:40Z</updated> <link rel="alternate" href="https://www.globenewswire.com/news-release/2020/10/28/2116311/10047/en/Acura-Pharmaceuticals-and-AD-Pharma-Amend-License-to-LIMITx-LTX-03.html" /> <category term="Other OTC:ACUR" scheme="https://www.globenewswire.com/rss/stock" /> <category term="US00509L8028" scheme="https://www.globenewswire.com/rss/ISIN" /> <content type="html"><![CDATA[Amendment Extends NDA Acceptance Date and Expands Agreement <pre>Amendment Extends NDA Acceptance Date and Expands Agreement</pre>]]></content> <dc:identifier>2116311</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>Acura Pharmaceuticals, Inc.</dc:contributor> <dc:modified>Wed, 28 Oct 2020 20:15 GMT</dc:modified> <dc:subject>Company Announcement</dc:subject> <dc:subject>Licensing Agreements</dc:subject> <dc:subject>Partnerships</dc:subject> <dc:subject>Product / Services Announcement</dc:subject> </entry> <entry> <id>https://www.globenewswire.com/news-release/2020/08/14/2078491/10047/en/Acura-Pharmaceuticals-Announces-Second-Quarter-2020-Financial-Results.html</id> <title type="text">Acura Pharmaceuticals Announces Second Quarter 2020 Financial Results</title> <published>2020-08-14T10:00:00Z</published> <updated>2024-12-15T00:21:40Z</updated> <link rel="alternate" href="https://www.globenewswire.com/news-release/2020/08/14/2078491/10047/en/Acura-Pharmaceuticals-Announces-Second-Quarter-2020-Financial-Results.html" /> <category term="Other OTC:ACUR" scheme="https://www.globenewswire.com/rss/stock" /> <category term="US00509L8028" scheme="https://www.globenewswire.com/rss/ISIN" /> <content type="html"><![CDATA[<p align="justify">PALATINE, Ill., Aug. 14, 2020 (GLOBE NEWSWIRE) -- Acura Pharmaceuticals, Inc. (OTCQB: ACUR), a specialty pharmaceutical company engaged in the research, development and commercialization of technologies and product candidates intended to mitigate the risk of outcomes associated with product misuse, announced today financial results for the three and six months ended June 30, 2020.<br></p>]]></content> <dc:identifier>2078491</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>Acura Pharmaceuticals, Inc.</dc:contributor> <dc:modified>Fri, 14 Aug 2020 10:00 GMT</dc:modified> <dc:subject>Earnings Releases and Operating Results</dc:subject> </entry> <entry> <id>https://www.globenewswire.com/news-release/2020/06/29/2054994/10047/en/Acura-Pharmaceuticals-Announces-First-Quarter-2020-Financial-Results.html</id> <title type="text">Acura Pharmaceuticals Announces First Quarter 2020 Financial Results</title> <published>2020-06-29T20:15:00Z</published> <updated>2024-12-15T00:21:40Z</updated> <link rel="alternate" href="https://www.globenewswire.com/news-release/2020/06/29/2054994/10047/en/Acura-Pharmaceuticals-Announces-First-Quarter-2020-Financial-Results.html" /> <category term="Other OTC:ACUR" scheme="https://www.globenewswire.com/rss/stock" /> <category term="US00509L8028" scheme="https://www.globenewswire.com/rss/ISIN" /> <content type="html"><![CDATA[<p align="justify">PALATINE, Ill., June 29, 2020 (GLOBE NEWSWIRE) -- Acura Pharmaceuticals, Inc. (OTCQB: ACUR), a specialty pharmaceutical company engaged in the research, development and commercialization of technologies and product candidates intended to mitigate the risk of outcomes associated with product misuse, announced today financial results for the three months ended March 31, 2020.<br></p>]]></content> <dc:identifier>2054994</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>Acura Pharmaceuticals, Inc.</dc:contributor> <dc:modified>Mon, 29 Jun 2020 20:15 GMT</dc:modified> <dc:subject>Earnings Releases and Operating Results</dc:subject> </entry> <entry> <id>https://www.globenewswire.com/news-release/2020/03/30/2008694/10047/en/Acura-Pharmaceuticals-Announces-Fourth-Quarter-and-Full-Year-2019-Financial-Results.html</id> <title type="text">Acura Pharmaceuticals Announces Fourth Quarter and Full Year 2019 Financial Results</title> <published>2020-03-30T20:15:00Z</published> <updated>2024-12-15T00:21:40Z</updated> <link rel="alternate" href="https://www.globenewswire.com/news-release/2020/03/30/2008694/10047/en/Acura-Pharmaceuticals-Announces-Fourth-Quarter-and-Full-Year-2019-Financial-Results.html" /> <category term="Other OTC:ACUR" scheme="https://www.globenewswire.com/rss/stock" /> <category term="US00509L8028" scheme="https://www.globenewswire.com/rss/ISIN" /> <content type="html"><![CDATA[<p align="justify">PALATINE, Ill., March 30, 2020 (GLOBE NEWSWIRE) -- Acura Pharmaceuticals, Inc., a specialty pharmaceutical company engaged in the research, development and commercialization of technologies and product candidates intended to mitigate the risk of outcomes associated with product misuse, announced today financial results for the three and twelve months ended December 31, 2019.<br></p>]]></content> <dc:identifier>2008694</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>Acura Pharmaceuticals, Inc.</dc:contributor> <dc:modified>Mon, 30 Mar 2020 20:15 GMT</dc:modified> <dc:subject>Earnings Releases and Operating Results</dc:subject> </entry> <entry> <id>https://www.globenewswire.com/news-release/2020/03/23/2005065/10047/en/Acura-Pharmaceuticals-Provides-an-Update-on-the-Development-of-LTX-03.html</id> <title type="text">Acura Pharmaceuticals Provides an Update on the Development of LTX-03</title> <published>2020-03-23T20:10:00Z</published> <updated>2024-12-15T00:21:40Z</updated> <link rel="alternate" href="https://www.globenewswire.com/news-release/2020/03/23/2005065/10047/en/Acura-Pharmaceuticals-Provides-an-Update-on-the-Development-of-LTX-03.html" /> <category term="Other OTC:ACUR" scheme="https://www.globenewswire.com/rss/stock" /> <category term="US00509L8028" scheme="https://www.globenewswire.com/rss/ISIN" /> <content type="html"><![CDATA[<p align="justify">PALATINE, Ill., March 23, 2020 (GLOBE NEWSWIRE) -- Acura Pharmaceuticals, Inc. (OTCQB: ACUR), today announced that Abuse Deterrent Pharma, LLC, its licensee of LTX-03 (Hydrocodone Bitartrate and Acetaminophen with Acura’s LIMITx™ Technology), has engaged Catalent Pharma Solutions, LLC (“Catalent”) to perform tablet manufacturing for clinical testing supplies of the product. Acura previously engaged Catalent to perform micro-particle process development for LTX-03 using hot-melt extrusion technology at Catalent’s Somerset, New Jersey facility before transferring to scaled production in Winchester, Kentucky, and which work is pending receipt of auxiliary manufacturing equipment expected in the next 30 days. Catalent is a leading provider of advanced delivery technologies, development and manufacturing solutions and has the expertise, technologies and scale to move products through development to commercialization.<br></p>]]></content> <dc:identifier>2005065</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>Acura Pharmaceuticals, Inc.</dc:contributor> <dc:modified>Mon, 23 Mar 2020 20:10 GMT</dc:modified> <dc:subject>Company Announcement</dc:subject> </entry> <entry> <id>https://www.globenewswire.com/news-release/2020/02/28/1992529/10047/en/Acura-Pharmaceuticals-Announces-Third-Quarter-2019-Financial-Results.html</id> <title type="text">Acura Pharmaceuticals Announces Third Quarter 2019 Financial Results</title> <published>2020-02-28T11:00:00Z</published> <updated>2024-12-15T00:21:40Z</updated> <link rel="alternate" href="https://www.globenewswire.com/news-release/2020/02/28/1992529/10047/en/Acura-Pharmaceuticals-Announces-Third-Quarter-2019-Financial-Results.html" /> <category term="Other OTC:ACUR" scheme="https://www.globenewswire.com/rss/stock" /> <category term="US00509L8028" scheme="https://www.globenewswire.com/rss/ISIN" /> <content type="html"><![CDATA[<p align="justify">PALATINE, Ill., Feb. 28, 2020 (GLOBE NEWSWIRE) -- Acura Pharmaceuticals, Inc. (OTC: ACUR), a specialty pharmaceutical company engaged in the research, development and commercialization of technologies and product candidates intended to mitigate the risk of outcomes associated with product misuse, announced today financial results for the three and nine months ended September 30, 2019.<br></p>]]></content> <dc:identifier>1992529</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>Acura Pharmaceuticals, Inc.</dc:contributor> <dc:modified>Fri, 28 Feb 2020 11:00 GMT</dc:modified> <dc:subject>Earnings Releases and Operating Results</dc:subject> </entry> <entry> <id>https://www.globenewswire.com/news-release/2020/02/10/1982643/10047/en/Acura-Pharmaceuticals-Announces-Second-Quarter-2019-Financial-Results.html</id> <title type="text">Acura Pharmaceuticals Announces Second Quarter 2019 Financial Results</title> <published>2020-02-10T21:15:00Z</published> <updated>2024-12-15T00:21:40Z</updated> <link rel="alternate" href="https://www.globenewswire.com/news-release/2020/02/10/1982643/10047/en/Acura-Pharmaceuticals-Announces-Second-Quarter-2019-Financial-Results.html" /> <category term="Other OTC:ACUR" scheme="https://www.globenewswire.com/rss/stock" /> <category term="US00509L8028" scheme="https://www.globenewswire.com/rss/ISIN" /> <content type="html"><![CDATA[<p align="left">PALATINE, Ill., Feb. 10, 2020 (GLOBE NEWSWIRE) -- Acura Pharmaceuticals, Inc., a specialty pharmaceutical company engaged in the research, development and commercialization of technologies and product candidates intended to mitigate the risk of outcomes associated with product misuse, announced today financial results for the three and six months ended June 30, 2019.<br></p>]]></content> <dc:identifier>1982643</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>Acura Pharmaceuticals, Inc.</dc:contributor> <dc:modified>Mon, 10 Feb 2020 21:15 GMT</dc:modified> <dc:subject>Earnings Releases and Operating Results</dc:subject> </entry> <entry> <id>https://www.globenewswire.com/news-release/2020/01/02/1965839/10047/en/Acura-Pharmaceuticals-Provides-an-Update-on-the-Development-of-LTX-03.html</id> <title type="text">Acura Pharmaceuticals Provides an Update on the Development of LTX-03</title> <published>2020-01-02T21:15:00Z</published> <updated>2024-12-15T00:21:40Z</updated> <link rel="alternate" href="https://www.globenewswire.com/news-release/2020/01/02/1965839/10047/en/Acura-Pharmaceuticals-Provides-an-Update-on-the-Development-of-LTX-03.html" /> <category term="Other OTC:ACUR" scheme="https://www.globenewswire.com/rss/stock" /> <category term="US00509L8028" scheme="https://www.globenewswire.com/rss/ISIN" /> <content type="html"><![CDATA[<p align="justify">PALATINE, Ill., Jan. 02, 2020 (GLOBE NEWSWIRE) -- Acura Pharmaceuticals, Inc. (OTC Pink: ACUR), today provided an update on its development of LTX-03 (Hydrocodone Bitartrate and Acetaminophen) Tablets using Acura’s LIMITx™ technology intended to mitigate risks associated with overdose of the hydrocodone. In conjunction with a third party formulation developer, the formulation and manufacturing process for LTX-03 has been optimized for commercial scale. Acura’s partnered commercial manufacturer has received hydrocodone quota from the Drug Enforcement Administration and is in the process of acquiring specific auxiliary equipment for the identified manufacturing process. Acura has also completed a non-clinical small animal study to identify the benefits of a reduction in peak plasma drug concentrations (Cmax) on opioid induced respiratory depression (OIRD).<br></p>]]></content> <dc:identifier>1965839</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>Acura Pharmaceuticals, Inc.</dc:contributor> <dc:modified>Thu, 02 Jan 2020 21:15 GMT</dc:modified> <dc:subject>Company Announcement</dc:subject> </entry> <entry> <id>https://www.globenewswire.com/news-release/2019/10/01/1923109/10047/en/Acura-Pharmaceuticals-Announces-First-Quarter-2019-Financial-Results.html</id> <title type="text">Acura Pharmaceuticals Announces First Quarter 2019 Financial Results</title> <published>2019-10-01T10:00:00Z</published> <updated>2024-12-15T00:21:40Z</updated> <link rel="alternate" href="https://www.globenewswire.com/news-release/2019/10/01/1923109/10047/en/Acura-Pharmaceuticals-Announces-First-Quarter-2019-Financial-Results.html" /> <category term="Other OTC:ACUR" scheme="https://www.globenewswire.com/rss/stock" /> <category term="US00509L8028" scheme="https://www.globenewswire.com/rss/ISIN" /> <content type="html"><![CDATA[<p align="justify">PALATINE, Ill., Oct. 01, 2019 (GLOBE NEWSWIRE) -- Acura Pharmaceuticals, Inc., a specialty pharmaceutical company engaged in the research, development and commercialization of technologies and product candidates intended to mitigate the risk of outcomes associated with product misuse announced, today financial results for the three months ended March 31, 2019.<br></p>]]></content> <dc:identifier>1923109</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>Acura Pharmaceuticals, Inc.</dc:contributor> <dc:modified>Tue, 01 Oct 2019 10:00 GMT</dc:modified> <dc:subject>Earnings Releases and Operating Results</dc:subject> </entry> <entry> <id>https://www.globenewswire.com/news-release/2019/09/16/1916286/10047/en/Acura-Pharmaceuticals-Announces-Fourth-Quarter-2018-and-Full-Year-2018-Financial-Results.html</id> <title type="text">Acura Pharmaceuticals Announces Fourth Quarter 2018 and Full Year 2018 Financial Results</title> <published>2019-09-16T20:15:00Z</published> <updated>2024-12-15T00:21:40Z</updated> <link rel="alternate" href="https://www.globenewswire.com/news-release/2019/09/16/1916286/10047/en/Acura-Pharmaceuticals-Announces-Fourth-Quarter-2018-and-Full-Year-2018-Financial-Results.html" /> <category term="Other OTC:ACUR" scheme="https://www.globenewswire.com/rss/stock" /> <category term="US00509L8028" scheme="https://www.globenewswire.com/rss/ISIN" /> <content type="html"><![CDATA[<p align="justify">PALATINE, Ill., Sept. 16, 2019 (GLOBE NEWSWIRE) -- Acura Pharmaceuticals, Inc., a specialty pharmaceutical company engaged in the research, development and commercialization of technologies and product candidates intended to mitigate the risk of outcomes associated with product misuse announced today financial results for the three and twelve months ended December 31, 2018.<br></p>]]></content> <dc:identifier>1916286</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>Acura Pharmaceuticals, Inc.</dc:contributor> <dc:modified>Mon, 16 Sep 2019 20:15 GMT</dc:modified> <dc:subject>Earnings Releases and Operating Results</dc:subject> </entry> </feed>